IBDEI048 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1685,1,5,0)
 ;;=5^PANCREATITIS,ACUTE
 ;;^UTILITY(U,$J,358.3,1685,2)
 ;;=^2643
 ;;^UTILITY(U,$J,358.3,1686,0)
 ;;=332.0^^18^158^4
 ;;^UTILITY(U,$J,358.3,1686,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1686,1,2,0)
 ;;=2^332.0
 ;;^UTILITY(U,$J,358.3,1686,1,5,0)
 ;;=5^PARKINSON'S DISEASE
 ;;^UTILITY(U,$J,358.3,1686,2)
 ;;=^304847
 ;;^UTILITY(U,$J,358.3,1687,0)
 ;;=420.91^^18^158^5
 ;;^UTILITY(U,$J,358.3,1687,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1687,1,2,0)
 ;;=2^420.91
 ;;^UTILITY(U,$J,358.3,1687,1,5,0)
 ;;=5^PERICARDITIS
 ;;^UTILITY(U,$J,358.3,1687,2)
 ;;=^269695
 ;;^UTILITY(U,$J,358.3,1688,0)
 ;;=462.^^18^158^6
 ;;^UTILITY(U,$J,358.3,1688,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1688,1,2,0)
 ;;=2^462.
 ;;^UTILITY(U,$J,358.3,1688,1,5,0)
 ;;=5^PHARYNGITIS,ACUTE
 ;;^UTILITY(U,$J,358.3,1688,2)
 ;;=^2653
 ;;^UTILITY(U,$J,358.3,1689,0)
 ;;=451.2^^18^158^7
 ;;^UTILITY(U,$J,358.3,1689,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1689,1,2,0)
 ;;=2^451.2
 ;;^UTILITY(U,$J,358.3,1689,1,5,0)
 ;;=5^PHLEBITIS
 ;;^UTILITY(U,$J,358.3,1689,2)
 ;;=^269813
 ;;^UTILITY(U,$J,358.3,1690,0)
 ;;=511.9^^18^158^8
 ;;^UTILITY(U,$J,358.3,1690,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1690,1,2,0)
 ;;=2^511.9
 ;;^UTILITY(U,$J,358.3,1690,1,5,0)
 ;;=5^PLEURAL EFFUSION NOS
 ;;^UTILITY(U,$J,358.3,1690,2)
 ;;=^123973
 ;;^UTILITY(U,$J,358.3,1691,0)
 ;;=511.0^^18^158^9
 ;;^UTILITY(U,$J,358.3,1691,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1691,1,2,0)
 ;;=2^511.0
 ;;^UTILITY(U,$J,358.3,1691,1,5,0)
 ;;=5^PLEURISY
 ;;^UTILITY(U,$J,358.3,1691,2)
 ;;=^95432
 ;;^UTILITY(U,$J,358.3,1692,0)
 ;;=486.^^18^158^10
 ;;^UTILITY(U,$J,358.3,1692,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1692,1,2,0)
 ;;=2^486.
 ;;^UTILITY(U,$J,358.3,1692,1,5,0)
 ;;=5^PNEUMONIA,UNSPEC
 ;;^UTILITY(U,$J,358.3,1692,2)
 ;;=^95632
 ;;^UTILITY(U,$J,358.3,1693,0)
 ;;=698.9^^18^158^11
 ;;^UTILITY(U,$J,358.3,1693,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1693,1,2,0)
 ;;=2^698.9
 ;;^UTILITY(U,$J,358.3,1693,1,5,0)
 ;;=5^PRURITUS
 ;;^UTILITY(U,$J,358.3,1693,2)
 ;;=^123977
 ;;^UTILITY(U,$J,358.3,1694,0)
 ;;=696.1^^18^158^12
 ;;^UTILITY(U,$J,358.3,1694,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1694,1,2,0)
 ;;=2^696.1
 ;;^UTILITY(U,$J,358.3,1694,1,5,0)
 ;;=5^PSORIASIS
 ;;^UTILITY(U,$J,358.3,1694,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,1695,0)
 ;;=454.9^^18^159^1
 ;;^UTILITY(U,$J,358.3,1695,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1695,1,2,0)
 ;;=2^454.9
 ;;^UTILITY(U,$J,358.3,1695,1,5,0)
 ;;=5^VARICOSE VEINS
 ;;^UTILITY(U,$J,358.3,1695,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,1696,0)
 ;;=780.4^^18^159^2
 ;;^UTILITY(U,$J,358.3,1696,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1696,1,2,0)
 ;;=2^780.4
 ;;^UTILITY(U,$J,358.3,1696,1,5,0)
 ;;=5^VERTIGO
 ;;^UTILITY(U,$J,358.3,1696,2)
 ;;=^35946
 ;;^UTILITY(U,$J,358.3,1697,0)
 ;;=079.99^^18^159^3
 ;;^UTILITY(U,$J,358.3,1697,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1697,1,2,0)
 ;;=2^079.99
 ;;^UTILITY(U,$J,358.3,1697,1,5,0)
 ;;=5^VIRAL SYNDROME
 ;;^UTILITY(U,$J,358.3,1697,2)
 ;;=^295798
 ;;^UTILITY(U,$J,358.3,1698,0)
 ;;=369.9^^18^159^4
 ;;^UTILITY(U,$J,358.3,1698,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1698,1,2,0)
 ;;=2^369.9
 ;;^UTILITY(U,$J,358.3,1698,1,5,0)
 ;;=5^VISUAL LOSS (ABN)
 ;;^UTILITY(U,$J,358.3,1698,2)
 ;;=^126769
 ;;^UTILITY(U,$J,358.3,1699,0)
 ;;=780.79^^18^159^5
 ;;^UTILITY(U,$J,358.3,1699,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1699,1,2,0)
 ;;=2^780.79
 ;;^UTILITY(U,$J,358.3,1699,1,5,0)
 ;;=5^WEAKNESS
 ;;^UTILITY(U,$J,358.3,1699,2)
 ;;=^73344
 ;;^UTILITY(U,$J,358.3,1700,0)
 ;;=783.21^^18^159^6
